




Supplemental Figure 2, A



Supplemental Figure 2, B





Supplemental Table 1. Genes that were significantly modulated by either tamoxifen, letrozole, BMS-754807 or tamoxifen/BMS-754807 or letrozole/ BMS-754807 with 5% of false discovery rate and 2-fold change when compared to the untreated control.

Supplemental Figure 1. Ingenuity Pathway Analysis to compare the top biological functions (**A**) and canonical pathways (**B**) differentially contributed by the genes that are modulated by each treatment condition.

Supplemental Figure 2. Densitometric analysis of western blot from indicated bands in Figure 4. A) Phospho-protein expression (P-IGF-1R, P-AKT at Serine 473, P-ERK) is calculated as a function of the respective total protein expression (IGF-1R, AKT, ERK1/2); B) Total ER and InsR are normalized to the housekeeping gene, actin.

Supplemental Figure 3. Reported absolute glucose readings in mg/DL during in vivo therapy.